Alliance Pharma plc (APH) - Total Liabilities
Based on the latest financial reports, Alliance Pharma plc (APH) has total liabilities worth GBX161.50 Million GBX (≈ $19.65K USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alliance Pharma plc - Total Liabilities Trend (1999–2024)
This chart illustrates how Alliance Pharma plc's total liabilities have evolved over time, based on quarterly financial data. See APH current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Alliance Pharma plc Competitors by Total Liabilities
The table below lists competitors of Alliance Pharma plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NCC Group plc
LSE:NCC
|
UK | GBX136.80 Million |
|
CASI Pharmaceuticals Inc
NASDAQ:CASI
|
USA | $53.05 Million |
|
Click Holdings Limited
NASDAQ:CLIK
|
USA | $2.55 Million |
|
Raja Ferry Port Public Company Limited
BK:RP
|
Thailand | ฿613.87 Million |
|
XTL Biopharmaceuticals Ltd
TA:XTLB
|
Israel | ILA3.12 Million |
|
Bank Permata Tbk
JK:BNLI
|
Indonesia | Rp216.27 Trillion |
|
California Software Company Limited
NSE:CALSOFT
|
India | Rs33.05 Million |
|
Baosheng Media Group Holdings Ltd
NASDAQ:BAOS
|
USA | $9.13 Million |
Liability Composition Analysis (1999–2024)
This chart breaks down Alliance Pharma plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see APH company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alliance Pharma plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alliance Pharma plc (1999–2024)
The table below shows the annual total liabilities of Alliance Pharma plc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX161.50 Million ≈ $19.65K |
-18.04% |
| 2023-12-31 | GBX197.05 Million ≈ $23.98K |
-21.10% |
| 2022-12-31 | GBX249.75 Million ≈ $30.39K |
+13.01% |
| 2021-12-31 | GBX221.00 Million ≈ $26.89K |
-3.02% |
| 2020-12-31 | GBX227.90 Million ≈ $27.73K |
+70.76% |
| 2019-12-31 | GBX133.46 Million ≈ $16.24K |
-11.86% |
| 2018-12-31 | GBX151.41 Million ≈ $18.42K |
+13.76% |
| 2017-12-31 | GBX133.10 Million ≈ $16.19K |
-5.92% |
| 2016-12-31 | GBX141.47 Million ≈ $17.21K |
+9.03% |
| 2015-12-31 | GBX129.75 Million ≈ $15.79K |
+249.85% |
| 2014-12-31 | GBX37.09 Million ≈ $4.51K |
-12.37% |
| 2013-12-31 | GBX42.32 Million ≈ $5.15K |
-13.23% |
| 2012-12-31 | GBX48.78 Million ≈ $5.93K |
+27.83% |
| 2011-12-31 | GBX38.16 Million ≈ $4.64K |
-7.65% |
| 2010-12-31 | GBX41.32 Million ≈ $5.03K |
+2.86% |
| 2009-12-31 | GBX40.17 Million ≈ $4.89K |
+0.26% |
| 2008-12-31 | GBX40.07 Million ≈ $4.87K |
+0.82% |
| 2007-12-31 | GBX39.74 Million ≈ $4.84K |
+5.59% |
| 2006-12-31 | GBX37.63 Million ≈ $4.58K |
+33.19% |
| 2005-12-31 | GBX28.26 Million ≈ $3.44K |
+2.86% |
| 2005-02-28 | GBX27.47 Million ≈ $3.34K |
+13.45% |
| 2004-02-29 | GBX24.21 Million ≈ $2.95K |
+15.26% |
| 2003-02-28 | GBX21.01 Million ≈ $2.56K |
+87038.12% |
| 2002-12-31 | GBX24.11K ≈ $2.93 |
-99.71% |
| 2002-02-28 | GBX8.29 Million ≈ $1.01K |
+144.28% |
| 2001-02-28 | GBX3.39 Million ≈ $412.71 |
-13.09% |
| 2000-02-29 | GBX3.90 Million ≈ $474.88 |
-39.53% |
| 1999-02-28 | GBX6.45 Million ≈ $785.27 |
-- |
About Alliance Pharma plc
Alliance Pharma plc, a holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated i… Read more